As CEO of MEDIPOST Inc., Ed Ahn is driving the global expansion of CARTISTEM — the world's first allogeneic stem cell therapy for knee osteoarthritis (OA) and advancing regenerative medicine innovations. With a deep commitment to translating scientific breakthroughs into real-world treatments, he is steering the company’s efforts to redefine the treatment landscape for degenerative diseases.
Recent developments, including a high-profile acquisition and key regulatory changes, point to a paradigm shift. Cell and gene therapy is becoming increasingly commercially viable, with the potential to improve the lives of millions.